Freeline Therapeutics Holdings (FRLN)

Freeline Therapeutics Holdings Stock Analysis & Ratings

FRLN Stock Chart & Stats

Day’s Range$0.72 - $0.7699
52-Week Range$0.65 - $15.40
Previous Close$0.75
Average Volume (3M)227.10K
Market Cap$49.11M
P/E Ratio-0.1
Next EarningsNov 03, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-6.86



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Freeline Therapeutics Holdings’s price range in the past 12 months?
Freeline Therapeutics Holdings lowest stock price was $0.65 and its highest was $15.40 in the past 12 months.
    What is Freeline Therapeutics Holdings’s market cap?
    Freeline Therapeutics Holdings’s market cap is $49.11M.
      What is Freeline Therapeutics Holdings’s price target?
      The average price target for Freeline Therapeutics Holdings is $13.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 1656.95% Increase from the current price of $0.759.
        What do analysts say about Freeline Therapeutics Holdings?
        Freeline Therapeutics Holdings’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Freeline Therapeutics Holdings’s upcoming earnings report date?
          Freeline Therapeutics Holdings’s upcoming earnings report date is Nov 03, 2022 which is in 167 days.
            How were Freeline Therapeutics Holdings’s earnings last quarter?
            Currently, no data Available
            Is Freeline Therapeutics Holdings overvalued?
            According to Wall Street analysts Freeline Therapeutics Holdings’s price is currently Undervalued.
              Does Freeline Therapeutics Holdings pay dividends?
              Freeline Therapeutics Holdings does not currently pay dividends.
              What is Freeline Therapeutics Holdings’s EPS estimate?
              Freeline Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Freeline Therapeutics Holdings have?
              Freeline Therapeutics Holdings has 64,730,000 shares outstanding.
                What happened to Freeline Therapeutics Holdings’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of Freeline Therapeutics Holdings?
                Currently, no hedge funds are holding shares in FRLN


                Freeline Therapeutics Holdings Stock Analysis

                The Freeline Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Freeline Therapeutics Holdings

                Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis